Literature DB >> 2328557

Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers.

C A Naranjo1, K E Kadlec, P Sanhueza, D Woodley-Remus, E M Sellers.   

Abstract

The effects of fluoxetine, a relatively selective long-acting serotonin uptake inhibitor, on the consumption of alcoholic and nonalcoholic drinks, cigarette smoking, and body weight were assessed in 29 men who were early stage problem drinkers. After a 2-week baseline, subjects were randomly assigned to receive 40 mg/day fluoxetine (n = 8), 60 mg/day fluoxetine (n = 11), or placebo (n = 10) for 4 weeks. Fluoxetine 60 mg/day decreased mean daily alcoholic drinks from (X +/- SEM) 8.3 +/- 0.7 during baseline to 6.9 +/- 0.7 and decreased total drinks per 14 days from 115.8 +/- 9.3 to 96.5 +/- 9.5 (p less than 0.01; 17.3% decrease from baseline), with no significant increase in days of abstinence. Neither 40 mg/day fluoxetine nor placebo had effects on intake of alcohol. Fluoxetine 60 mg/day decreased total and mean daily alcoholic drinks compared with 40 mg/day fluoxetine (ANCOVA, both p less than 0.02), but neither dose of fluoxetine was different from placebo. Compared with placebo, both 40 mg/day fluoxetine and 60 mg/day fluoxetine no differences were detected between treatment groups, 60 mg/day fluoxetine increased mean daily nonalcoholic beverages from baseline (5.0 +/- 0.4 to 5.6 +/- 0.3, p less than 0.01) and increased daily cigarettes smoked (from 25.1 +/- 4.6 to 26.9 +/- 4.5, p less than 0.05), whereas no significant changes from baseline were observed with 40 mg/day fluoxetine or placebo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328557     DOI: 10.1038/clpt.1990.62

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

Review 1.  An experimental approach to understanding the genetic and neurobiological basis of alcoholism.

Authors:  T K Li; L Lumeng; W J McBride; J M Murphy
Journal:  Trans Am Clin Climatol Assoc       Date:  1993

Review 2.  Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

Authors:  Leah R Zindel; Henry R Kranzler
Journal:  J Stud Alcohol Drugs Suppl       Date:  2014

Review 3.  Clinical issues related to the costs of alcoholism.

Authors:  M O Howard; R W McGuffin; A J Saxon; K L Sloan; R D Walker
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

4.  Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial.

Authors:  Denise A Hien; Frances Rudnick Levin; Lesia M Ruglass; Teresa López-Castro; Santiago Papini; Mei-Chen Hu; Lisa Renee Cohen; Abigail Herron
Journal:  J Consult Clin Psychol       Date:  2015-01-26

5.  Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats.

Authors:  F Weiss; L H Parsons; G Schulteis; P Hyytiä; M T Lorang; F E Bloom; G F Koob
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

Review 6.  Role of the serotonergic system in alcohol dependence: from animal models to clinics.

Authors:  Youssef Sari; Verity R Johnson; Jason M Weedman
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

7.  A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype.

Authors:  Henry R Kranzler; Stephen Armeli; Howard Tennen; Jonathan Covault; Richard Feinn; Albert J Arias; Helen Pettinati; Cheryl Oncken
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

Review 8.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

9.  Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.

Authors:  John D Roache; Yanmei Wang; Nassima Ait-Daoud; Bankole A Johnson
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

Review 10.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.